NCT00220064View on ClinicalTrials.gov

A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours

PHASE2CompletedINTERVENTIONAL

Enrollment

65

Participants

Timeline

Start Date

July 31, 2000

Study Completion Date

November 30, 2005

Conditions

Upper Gastrointestinal Tumours

Interventions

DRUG

Irinotecan, 5-Fluorouracil, Leucovorin

Sponsors

Collaborators (1)

Aventis Pharmaceuticals

All Listed Sponsors

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

Royal Marsden NHS Foundation Trust

OTHER